It took a while, but healthcare giant Johnson & Johnson (NYSE:JNJ) is once again delivering on its potential as a triple-threat in drugs, devices, and OTC consumer and health products. Strong growth in the drug and devices business is very much welcome, but now the question becomes whether management can lead a similar turnaround in OTC. Although J&J looks to be on the cusp of being a good buy, ongoing outperformance does seem predicated on a more well-rounded growth profile in the coming years.

Forex Broker Guide: Using the right broker is essential when competing in today's forex marketplace.

Once Again a Growth Story
J&J's revenue for the third quarter was only slightly above the average analyst's guess, but organic growth of over 5% is quite a good result in the healthcare sector today. Growth was driven solely by the company's pharmaceutical and devices businesses, where revenue increased more than 11% and 16% respectively. Although the consumer segment was a positive contributor, it did not impress with 1% adjusted revenue growth. Although the profitability numbers require a little explanation, the overall performance was solid. Gross margin did slip over 100 basis points from last year, due in part to ongoing remediation costs in the consumer business and licensing costs in the drug business. Operating income rose 9%, however, as the company did see solid SG&A leverage.

Pharma Back in Black
It has taken several years and a lot of deals (both acquisitions and in-licensing), but J&J's drug business is back to good health. Importantly, it's not just a new drug story - drugs such as Zytiga and Xarelto are certainly contributing to growth, but older drugs such as Remicade, Concerta and Stelara continue to deliver solid performances as well. Although J&J has been getting credit for this improved performance in pharmaceuticals, an argument could be made that the company is still not getting full credit for its pipeline. Like Pfizer (NYSE:PFE) and AstraZeneca (NYSE:AZN), J&J is working on oral immunology drugs, as well as looking to expand its biologics franchise. Moreover, while J&J may not deserve as much attention for its hepatitis C research as Gilead (Nasdaq:GILD) or Abbott (NYSE:ABT), it's hardly an also-ran effort.

Still Some Work to Do in Devices
In contrast to the drug business, some may see J&J's device business lacking in near-term catalysts, despite it's recent positive quarter. Some of this can be tied to macroeconomic issues outside of the company's control - relative to prescription drugs, the co-pays and deductibles for device-based interventions have gotten worse and hospitals have pushed back aggressively on device costs. That said, whatever the reason may be, management needs to focus on keeping this business on a growth track. The company's orthopedic business is looking a little better, but I have to wonder if some of this is a product of turbulence at Stryker (NYSE:SYK). Elsewhere, the surgical business seems soft relative to the recent performance of Covidien (NYSE:COV), and the performance of the diagnostics business is not impressive. Diabetes is also weak, but this is increasingly looking like an industry-wide malaise.

The Bottom Line
The good and bad of J&J is that it's never a pure-play on much of anything; it has been a while since all three business units have really been strong at the same time. In any case, J&J looks like one of the stronger pharmaceutical stories in the space right now, while the device business isn't markedly softer than most other major medical device players such as Medtronic (NYSE:MDT). The last couple of years have been below-trend for J&J. The reason that matters is that a projected free cash flow (FCF) growth rate of 7% might sound too aggressive for a company of its size, but at least 20% of that can be tied to simply getting back to historical levels of free cash flow conversion. In any case, if J&J can continue to post low-to-mid single-digit revenue growth and modest free cash flow conversion improvements, it's not hard to argue for a fair value over $80. That's not massive undervaluation, but when the dividend yield is included, I'd argue it makes this a worthwhile stock to consider for value- and income-oriented investors.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  4. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  5. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  6. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  7. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  8. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  9. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  10. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center